EMAIL DETAILS
SUBJECT:
Fwd: Potential acquisition targets for China Grand Enterprises
PRI: NORMAL
FROM:
D
devon@rstp.com
DATE:
2015-07-03 11:39:16
MSG_ID:
<78F970DB-8088-42E8-A41E-1FAFEBD857A1@rstp.com>
RECIPIENTS:
TO:
E
Eric D. Schwerin
<eschwerin@rosemontseneca.com>
H
Hunter Biden
<hbiden@rosemontseneca.com>
CONTENT:
TEXT: YES |
HTML: YES
PROCESSED
Devon D. Archer 646 436 3745 Begin forwarded message: > From: 王昕 <xin.wang@bhrpe.com> > Date: July 3, 2015 at 12:25:22 AM EDT > To: "'James Bulger'" <jbulger@thorntonai.com>, "'Devon Archer'" <devon@rstp.com> > Subject: Potential acquisition targets for China Grand Enterprises > > Gentlemen, > > As discussed on last night’s call, below is a list of U.S.-based medical companies in which China Grand Enterprises are interested in investing. I have also, to the extent available, identified some of the key management in case you know any of them. Any insight / information would be much appreciated. We hope to be able to replicate our relationship with AVIC with China Grand so that going forward, any acquisitions to be made by China Grand will be done in conjunction with BHR. Thanks. > > 1. Aceto Corp. (NASDAQ-GS: ACET) > Albert Eilender (Chairman) > Salvatore Guccione (CEO) > Douglas Rotn (CFO) > > 2. Amerigen Pharmaceuticals > John Lowry (CEO) > Ed Borkowski (CFO) > Jonathan Embleton > > 3. Benvenue Medical > Robert Weigle (CEO) > Laurent Schaller (Founder / CTO) > Jeffrey Jones (COO) > Oliver Brouse (VP Finance) > > 4. ANI Pharmaceuticals (NASDAQ: ANIP) > Arthur Przybyl (CEO) > Robert Brown (Chairman) > Charlotte Arnold (CFO) > > 5. Areva Pharmaceuticals > Irene Swaminathan (Chairman) > Victor Swaminathan (President) > Greg Olson (COO) > Jim Eveslage (CFO) > > 6. IGI Laboratories (AMEX: IG) > > 7. Sagent Pharmaceuticals (NASDAQ: SGNT) > > 8. Coherus Biosciences (NASDAQ: CHRS) > Dennis Lanfear (President / CEO / Chairman) > Jean-Frederic Viret (CFO) > Barbara Finck (Chief Medical Officer) > > 9. EPIRUS Biopharmaceuticals (NASDAQ: EPRS) > Amit Munshi (President / CEO) > Tom Shea (CFO) > Michael Wyand (CTO) > > 10. Pfenex (NYSE: PFHX) > Bertrand Liang (Founder / CEO) > Paul A. Wagner (CFO) > Patricia Lady (Chief Accountant) > > 11. Aprecia Pharmaceuticals > E. Thomas Arington (Chairman) > Don Wetherhold (CEO) > Mahendra Patel (Chief Science Officer) > Dave Furniss > Mike Rohlfs (CFO) > Rob Williford (COO) > > 12. BioDelivery Sciences International (NASDAQ BDSI) > Mark Sirigo (President / CEO) > Ernest De Paolantinio (CFO) > > 13. Pernix Therapeutics (NASDAQ: PTX) > > 14. TOLMAR > Michael Duncan (CEO) > =2
METADATA:
THREAD:
INDEX:
AdhhnZZ5ux4lnVumSWyjkHrph2oTWQ==
REFERENCES:
REFS:
<002701d0b548$47892f30$d69b8d90$@bhrpe.com>